论文部分内容阅读
目的评价参脉注射液联合左卡尼汀治疗慢性肺源性心脏病(CPHD)合并心力衰竭的临床疗效及安全性。方法将128例CPHD合并心力衰竭患者随机分为试验组66和对照组62例。对照组予以静脉滴注左卡尼汀3 g,每天1次;试验组在对照组的基础上,联合静脉滴注参麦注射液100 m L,每天1次。2组患者均治疗3周。比较2组患者的临床疗效、心功能改善情况及不良反应发生率。结果治疗后,试验组的总有效率为95.45%,显著高于对照组的85.48%(P<0.05)。治疗后,2组患者的心功能情况较治疗前显著改善,且试验组改善程度明显优于对照组(P<0.05)。2组患者治疗期间均无不良反应发生。结论参脉注射液联合左卡尼汀治疗CPHD合并心力衰竭能有效地提高患者的临床疗效,且用药安全。
Objective To evaluate the clinical efficacy and safety of Shenmai injection combined with levocarnitine in the treatment of chronic pulmonary heart disease (CPHD) complicated with heart failure. Methods 128 cases of CPHD complicated with heart failure were randomly divided into experimental group 66 and control group 62 cases. The control group was given intravenous infusion of levocarnitine 3 g once daily. On the basis of the control group, the experimental group was given intravenous infusion of Shenmai injection 100 m L once daily. Two groups of patients were treated for 3 weeks. The clinical efficacy, cardiac function improvement and incidence of adverse reactions in two groups were compared. Results After treatment, the total effective rate of the experimental group was 95.45%, which was significantly higher than that of the control group (85.48%, P <0.05). After treatment, the cardiac function of the two groups was significantly improved compared with that before treatment, and the improvement in the experimental group was significantly better than that in the control group (P <0.05). No adverse reactions occurred in the two groups during treatment. Conclusion Shenmai injection combined with levocarnitine in the treatment of CPHD complicated with heart failure can effectively improve the clinical efficacy of patients and medication safety.